REGULATION OF THE PTEN GENE IN PROSTATE CANCER
PTEN 基因在前列腺癌中的调控
基本信息
- 批准号:6166048
- 负责人:
- 金额:$ 27.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-07-17 至 2005-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The PTEN tumor suppressor gene plays a critical role in a number of human cancers, including prostate. PTEN encodes a lipid phosphatase that plays a key role in regulating the PI3- kinase/Akt signaling pathway, providing a compelling explanation of why loss of PTEN function leads to cancer. Our group has shown that: (i) PTEN unction is lost in up to 50 percent of advanced prostate cancers; (ii) PTEN regulates the PI3-kinase/Akt pathway in prostate cancer cells; (iii) PTEN binds a multi-PDZ scaffold protein (MAGI-2) in prostate and brain cells and (iv) MAGI-2 can regulate the phosphatase activity of PTEN. Here we propose to characterize the regulation of PTEN by MAGI-2 in detail by examining the effect of MAGI-2 on the tumor suppressor activity of PTEN and by examining the importance of the MAGI-2/PTEN complex in maintaining the integrity of signaling through the PI3-kinase/Akt pathway. We will also examine the possibility that MAGI-2 itself may play a role in oncogenesis through studies of its expression profile in prostate and brain cancers. Finally, we will study the importance of the MAGI-2/PTEN interaction in the context of a whole animal by creating targeted deletions of the MAGI-2 binding domain in the C-terminus of PTEN and by creating a MAGI-2 knockout mouse. Together, these experiments will define a novel mode of PTEN regulation in human cancers.
PTEN抑癌基因在包括前列腺癌在内的许多人类癌症中起着关键作用。PTEN编码一种在调节PI3-激酶/Akt信号通路中起关键作用的脂质磷酸酶,为PTEN功能丧失导致癌症提供了令人信服的解释。我们的研究小组发现:(I)PTEN功能在高达50%的晚期前列腺癌中缺失;(Ii)PTEN调控前列腺癌细胞中的PI3-Kinase/Akt通路;(Iii)PTEN与前列腺和脑细胞中的多PDZ支架蛋白(MAGI-2)结合;以及(Iv)MAGI-2可以调节PTEN的磷酸酶活性。在这里,我们建议通过检测MAGI-2对PTEN抑瘤活性的影响以及MAGI-2/PTEN复合体在维持PI3-K/Akt通路信号完整性中的重要性来详细描述MAGI-2对PTEN的调节。我们还将通过研究MAGI-2在前列腺癌和脑癌中的表达情况,来研究MAGI-2本身可能在肿瘤发生中发挥作用的可能性。最后,我们将通过在PTEN的C末端创建有针对性的MAGI-2结合结构域的缺失和通过创建MAGI-2基因敲除小鼠来研究MAGI-2/PTEN相互作用在整个动物中的重要性。总之,这些实验将在人类癌症中定义一种新的PTEN调控模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES L. SAWYERS其他文献
CHARLES L. SAWYERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES L. SAWYERS', 18)}}的其他基金
Molecular Biology in Clinical Oncology Workshop
临床肿瘤学分子生物学研讨会
- 批准号:
10712907 - 财政年份:2022
- 资助金额:
$ 27.22万 - 项目类别:
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
项目1:促进前列腺腺癌进展和去势反应的免疫和基质因子的研究
- 批准号:
10612347 - 财政年份:2022
- 资助金额:
$ 27.22万 - 项目类别:
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
项目1:促进前列腺腺癌进展和去势反应的免疫和基质因子的研究
- 批准号:
10333943 - 财政年份:2022
- 资助金额:
$ 27.22万 - 项目类别:
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer
前列腺癌 DNA 损伤修复变异体的功能评估和解释
- 批准号:
10708050 - 财政年份:2019
- 资助金额:
$ 27.22万 - 项目类别:
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer
前列腺癌 DNA 损伤修复变异体的功能评估和解释
- 批准号:
9792982 - 财政年份:2019
- 资助金额:
$ 27.22万 - 项目类别:
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer
前列腺癌 DNA 损伤修复变异体的功能评估和解释
- 批准号:
10495179 - 财政年份:2019
- 资助金额:
$ 27.22万 - 项目类别:
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer
前列腺癌 DNA 损伤修复变异体的功能评估和解释
- 批准号:
10003304 - 财政年份:2019
- 资助金额:
$ 27.22万 - 项目类别:
Project 1: Resistance caused by AR pathway reactivation
项目1:AR通路重新激活引起的耐药
- 批准号:
10250361 - 财政年份:2017
- 资助金额:
$ 27.22万 - 项目类别:
Project 1: Resistance caused by AR pathway reactivation
项目1:AR通路重新激活引起的耐药
- 批准号:
10005210 - 财政年份:2017
- 资助金额:
$ 27.22万 - 项目类别:
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center
MSKCC-UW/Fred Hutch 前列腺癌耐药性和敏感性中心
- 批准号:
10250359 - 财政年份:2017
- 资助金额:
$ 27.22万 - 项目类别: